SETD2 and neoplasm: Importantly, novel molecular markers were found:MAML3 (mastermind-like protein 3) fusions,SETD2 (SET domain containing 2) orATRX somatic mutations, and WNT-related expression subtype, which comprise the tumours withMAML3 fusion tumours4.